MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Nabriva Therapeutics AG - Company Profile (NASDAQ:NBRV)

Consensus Ratings for Nabriva Therapeutics AG - (NASDAQ:NBRV) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $17.40 (138.68% upside)

Analysts' Ratings History for Nabriva Therapeutics AG - (NASDAQ:NBRV)
Show:
DateFirmActionRatingPrice TargetActions
4/27/2016WedbushReiterated RatingOutperform$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2016GabelliInitiated CoverageBuy$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/12/2015Needham & Company LLCReiterated RatingBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/12/2015RBC CapitalBoost Price TargetOutperform$21.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/13/2015Leerink SwannInitiated CoverageOutperform$10.00 -> $19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for Nabriva Therapeutics AG - (NASDAQ:NBRV)
No earnings announcements for this company have been tracked by MarketBeat.com

Earnings Estimates for Nabriva Therapeutics AG - (NASDAQ:NBRV)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.55)($0.55)($0.55)
Q2 20161($0.58)($0.58)($0.58)
Q3 20161($0.58)($0.58)($0.58)
Q4 20161($0.48)($0.48)($0.48)
(Data provided by Zacks Investment Research)
Dividend History for Nabriva Therapeutics AG - (NASDAQ:NBRV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Nabriva Therapeutics AG - (NASDAQ:NBRV)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Nabriva Therapeutics AG - (NASDAQ:NBRV)
DateHeadline
06/20/16 05:16 PMNabriva Presents Data on Lefamulin at the American Society of Microbiology (ASM) Microbe 2016 Conference
06/14/16 06:19 AMNabriva to Present at the JMP Securities Life Sciences Conference - [at noodls] - VIENNA, Austria and KING OF PRUSSIA, Pa., June 14, 2016 (GLOBE NEWSWIRE) -- (NASDAQ:NBRV) - Nabriva Therapeutics AG, a clinical stage biopharmaceutical company engaged in the research and development of ...
06/06/16 01:31 PMNabriva Therapeutics AG :NBRV-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 -
06/01/16 05:52 PMNabriva Therapeutics AG (US: NBRV) to Ring The Nasdaq Stock Market Closing Bell - Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK Social Media:For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our ...
05/31/16 09:22 AMNabriva Therapeutics AG (Nasdaq: NBRV) to Ring The Nasdaq Stock Market Closing Bell - [at noodls] - ADVISORY, May 31, 2016 (GLOBE NEWSWIRE) -- What: Nabriva Therapeutics AG (Nasdaq:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents ...
05/16/16 06:32 AMNabriva Announces Lefamulin Presentation at ASM Microbe 2016 Conference - [at noodls] - VIENNA, Austria and KING OF PRUSSIA, Pa., May 16, 2016 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel ...
05/11/16 06:22 AMNabriva to Present at the UBS Global Healthcare Conference - [at noodls] - VIENNA, Austria and KING OF PRUSSIA, Pa., May 11, 2016 (GLOBE NEWSWIRE) -- (NASDAQ:NBRV) - Nabriva Therapeutics AG, a clinical stage biopharmaceutical company engaged in the research and development of ...
05/10/16 06:18 AMNabriva Reports First Quarter 2016 Financial Results - [at noodls] - March 31, 2015 ney1 1.4 mili aeo a its financen ofensy> for the three months ended March 31, 2016 DuoffesFor the three months ended March 31, 2016$0.9 million AgreeenBP, afrom fKreosdata, whase fulmarstp�� ...
05/05/16 12:04 PMNABRIVA THERAPEUTICS AG Financials -
05/02/16 06:10 AMNabriva Appoints Gary Sender as Chief Financial Officer - [at noodls] - VIENNA, Austria and KING OF PRUSSIA, Pa., May 02, 2016 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel ...
05/02/16 06:00 AM7:00 am Nabriva Therapeutics appoints Gary Sender as CFO, effective immediately -
04/27/16 07:30 AMNabriva Therapeutics AG Earnings Call scheduled for 8:30 am ET today -
04/27/16 06:21 AMNabriva Therapeutics AG Reports Full Year 2015 Financial Results and Provides Development Update - [at noodls] - VIENNA, Austria and KING OF PRUSSIA, Pa., April 27, 2016 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of ...
04/27/16 06:07 AMQ4 2015 Nabriva Therapeutics AG Earnings Release - Before Market Open -
04/19/16 06:15 AMNabriva Therapeutics AG to Provide Development Update and Announce Full Year 2015 Financial Results; Conference Call on Wednesday, April 27, 2016 - [at noodls] - VIENNA, Austria and KING OF PRUSSIA, Pa., April 19, 2016 (GLOBE NEWSWIRE) -- (NASDAQ:NBRV) Nabriva Therapeutics AG, a clinical stage biopharmaceutical company engaged in the research and development of ...
04/15/16 11:10 AMNabriva Therapeutics (NASDAQ:NBRV) Initiates 2nd Phase III Trials of Lefamulin - Nabriva Therapeutics (NASDAQ:NBRV) has announced that it will embark on the second ... lefamulin against oral moxifloxacin in moderate CABP cases. Nabriva Therapeutics AG is a biopharmaceutical company that engages in research and development of the ...
04/11/16 07:20 AMNabriva Initiates Second Phase 3 Clinical Trial of Lefamulin (“LEAP 2”) in Patients with Community-Acquired Bacterial Pneumonia (CABP) - [at noodls] - Qualified Infectious Disease Product (QIDP) status granted for oral lefamulin formulation Top-line data from LEAP 2 study expected in 2H17 VIENNA, Austria, and KING OF PRUSSIA, Pa., April 11, 2016 (GLOBE ...
04/05/16 06:17 AMNabriva Therapeutics AG to Present at the 15th Annual Needham Healthcare Conference - [at noodls] - VIENNA, Austria and KING OF PRUSSIA, Pa., April 05, 2016 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of ...
03/31/16 09:53 AMAverage Rating Watch Nabriva Therapeutics AG - ADR (NASDAQ:NBRV) - Covering sell-side analysts have a current quarter earnings per share estimate of $0.59. (NASDAQ:PSDV). Data from Beta Systems research watches crowd sourced sentiment and compiles consensus stock ratings. This information is gathered from investors and ...
03/28/16 08:07 AM[$$] Iterum Therapeutics Secures $40M Series A, Licenses Anti-Infective Drug -
02/03/16 06:00 AMNabriva Therapeutics AG to Participate in Two Investor Conferences in February - [GlobeNewswire] - VIENNA, Austria and KING OF PRUSSIA, Pa., Feb. 03, 2016-- Nabriva Therapeutics AG, a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents, with ...
01/27/16 08:07 AMCoverage initiated on Nabriva Therapeutics by Gabelli & Co -
01/21/16 07:56 AMNabriva Therapeutics AG (NBRV) - Nabriva Therapeutics AG, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate ...
11/27/15 08:42 AMDo Hedge Funds Love Lawson Products, Inc. (LAWS)? -
11/11/15 06:26 AMNabriva Therapeutics AG Provides Development Update and Reports Nine Month 2015 Financial Results - [at noodls] - VIENNA, Austria and KING OF PRUSSIA, Pa., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of ...
11/11/15 06:07 AMQ3 2015 Nabriva Therapeutics AG Earnings Release - Before Market Open -
11/04/15 06:27 AMNabriva Therapeutics AG to Provide Development Update and Announce Nine Month 2015 Financial Results; Conference Call on Wednesday, November 11, 2015 - [at noodls] - VIENNA, Austria and KING Of PRUSSIA, Pa., Nov. 4, 2015 (GLOBE NEWSWIRE) -- (NASDAQ:NBRV) Nabriva Therapeutics AG, a clinical stage biopharmaceutical company engaged in the research and development of novel ...
10/05/15 11:57 AMThese Two Healthcare Stocks Receive A Vote Of Confidence From Elite Hedge Fund Managers -
09/23/15 03:35 PMNabriva Therapeutics Announces Closing of Its Initial Public Offering - [at noodls] - VIENNA, Austria and KING OF PRUSSIA, Pa., Sept. 23, 2015 (GLOBE NEWSWIRE) -- (NASDAQ: NBRV) - Nabriva Therapeutics AG announced today the closing of its initial public offering of 9,000,000 American Depositary ...
09/21/15 01:05 PMNabriva Therapeutics Prices Initial Public Offering - [at noodls] - Vienna, Austria / King of Prussia, Pennsylvania, Sept. 17, 2015 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG announced today the pricing of its initial public offering of 9,000,000 American Depositary Shares ...
09/20/15 11:35 PMInitial Public Offering of Nabriva Therapeutics - [at noodls] - NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA Media Release Zug, 21 September 2015 Nabriva Therapeutics (NASDAQ: NBRV), a company in the portfolio of HBM Healthcare Investments, has successfully ...
09/20/15 08:38 AMIPO Calendar Shows 3 Offerings on Tap for the Coming Week -
09/17/15 03:20 PMIPO Stock Watch: Regenxbio Jumps On First Trading Day -
09/16/15 05:22 PMRegenxbio Turns In Strong, Upsized IPO Performance -
About Nabriva Therapeutics AG -

Nabriva Therapeutics AG - logoNabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin, a Phase Two plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), and BC-7013, a Phase One topical pleuromutilin treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSSSIs). In addition, the Company has completed a Phase Two clinical trial for acute bacterial skin and skin structure infections (ABSSSI) and in Discovery Phase development of extended-spectrum pleuromutilins (ESPs), a pleuromutilin compound that treats Gram-negative bacteria. The Company is a spin-off of Sandoz GmbH and receives investment from HBM Healthcare Investments, Novartis Venture Fund, Omega Funds, OrbiMed Healthcare Fund Management, Phase4 Partners, Vivo Capital and the Wellcome Trust.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NBRV
  • CUSIP:
Key Metrics:
  • Previous Close: $7.29
  • 50 Day Moving Average: $7.71
  • 200 Day Moving Average: $8.42
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $154.45M
  • Current Quarter EPS Consensus Estimate: $-19.86 EPS
Additional Links:
Nabriva Therapeutics AG - (NASDAQ:NBRV) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha